PEOPLE - Changes at DiagnoCure:
This article was originally published in Clinica
Camille Chypre, vice-president of R&D, will be leaving Canadian cancer test developer DiagnoCure. Until a replacement for Dr Chypre is appointed, Dr Yves Fradet, senior vice-president and chief scientific officer, Lyson Piche, director of R&D, will temporarily take on his duties. Pierre Desy, president and CEO, stressed that Dr Chypre's departure would "not impact the timing of any current development projects" at the Quebec City, Quebec-based company.
You may also be interested in...
Dr Reddy’s sees its Indian domestic market and China as hot prospects as it pursues its “transformation journey” in which it is reducing its dependence on the slowing US market.
Glenmark has struck a deal with private equity firm True North for its gynecology business in India and Nepal.